NLS Pharmaceutics Closes Private Placement, Eyes Nasdaq Compliance
Ticker: NCEL · Form: 6-K · Filed: Oct 15, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: financing, compliance, listing
Related Tickers: NLS
TL;DR
NLS Pharmaceutics closed a private placement, likely saving their Nasdaq listing.
AI Summary
On October 15, 2024, NLS Pharmaceutics Ltd. announced the closing of a private placement, which is expected to bring the company into compliance with Nasdaq's continued listing rules. The company filed a Form 6-K to report this event, incorporating a press release detailing the private placement.
Why It Matters
This private placement is crucial for NLS Pharmaceutics as it addresses potential delisting from Nasdaq, ensuring continued trading and investor confidence.
Risk Assessment
Risk Level: medium — While the private placement aims to resolve Nasdaq listing issues, the success and long-term implications of the placement are not fully detailed, introducing some uncertainty.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- Nasdaq (company) — Stock exchange where listing compliance is sought
- October 15, 2024 (date) — Date of press release and filing
FAQ
What was the primary purpose of the private placement announced by NLS Pharmaceutics?
The primary purpose was to achieve compliance with Nasdaq's continued listing rules.
When did NLS Pharmaceutics announce the closing of this private placement?
The announcement was made on October 15, 2024.
What form was filed with the SEC to report this event?
A Form 6-K was filed with the SEC.
What is the company's principal executive office address?
The company's principal executive offices are located at The Circle 6, 8058 Zurich, Switzerland.
Which SEC registration statements does this Form 6-K filing incorporate by reference?
This Form 6-K filing is incorporated by reference into the Company's Registration Statements on Form F-3, File Numbers 333-262489, 333-268690, and 333-269220.
Filing Stats: 274 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2024-10-15 09:09:19
Filing Documents
- ea0217575-6k_nlspharm.htm (6-K) — 12KB
- ea021757501ex99-1_nlspharm.htm (EX-99.1) — 8KB
- 0001213900-24-087508.txt ( ) — 22KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: October 15, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 3